1560 TRAPELO ROAD, WALTHAM, MA
Changes in Board, Management or Compensation
Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Material Contracts, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Investor Presentation
Shareholder votes
Earnings Release
Annual Report to Security Holders
Q2
Q1
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities